Effect of Digital Medication Event Reminder and Monitor-Observed Therapy vs Standard Directly Observed Therapy on Health-Related Quality of Life and Catastrophic Costs in Patients With Tuberculosis

Abstract

IMPORTANCELittle is known about whether digital adherence technologies are economical for patients with tuberculosis (TB) in resource-constrained settings.OBJECTIVE To test the hypothesis that for patients with TB, a digital medication event reminder monitor (MERM)-observed therapy provides higher health-related quality of life (HRQoL) and lower catastrophic costs compared with standard directly observed therapy (DOT). DESIGN, SETTING, AND PARTICIPANTSThis study was a secondary analysis of a randomized, 2-arm, open-label trial conducted in 10 health care facilities in Ethiopia. Eligible participants were adults with new or previously treated, bacteriologically confirmed, drug-sensitive pulmonary TB who were eligible to start first-line anti-TB therapy. Participants were enrolled between June 2, 2020, and June 15, 2021, with the last participant completing follow-up on August 15, 2021. INTERVENTIONS Participants were randomly assigned (1:1) to receive a 15-day TB medication supply dispensed with a MERM device to self-administer and return every 15 days (intervention arm) or the standard in-person DOT (control arm). Both groups were observed throughout the standard 2-month intensive treatment phase. MAIN OUTCOMES AND MEASURESPrespecified secondary end points of the original trial were HRQoL using the EuroQoL 5-dimension 5-level (EQ-5D-5L) tool and catastrophic costs, direct (out-ofpocket) and indirect (guardian and coping) costs from the individual patient perspective using the World Health Organization's Tool to Estimate Patient Costs, and common factors associated with lower HRQoL and higher catastrophic costs. RESULTS Among 337 patients screened for eligibility, 114 were randomly assigned, and 109 were included in the final complete-case intention-to-treat analysis (57 control and 52 intervention participants). The mean (SD) age was 33.1 (11.1) years; 72 participants (66.1%) were men, and 15 (13.9%) had HIV coinfection. EQ-5D-5L overall median (IQR) index value was 0.964 (0.907-1). The median (IQR) value was significantly higher in intervention (1 [0.974-1]) vs control (.908 [0.891-0.964]) (P < .001). EQ-5D-5L minimum and maximum health state utility values in intervention were 0.906 and 1 vs 0.832 and 1 in control. Patients' overall median (IQR) postdiagnosis cost was Ethiopian birr (ETB) 80 (ETB 16-ETB 480) (US $1.53). The median cost was significantly lower in intervention ) vs control (ETB 432 [ETB 210-ETB 1980]) (P < .001), with median possible cost savings of ETB 336 (ETB 156-ETB 1339) (US $6.44) vs the control arm.Overall, 42 participants (38.5%; 95% CI, 29.4%-48.3%) faced catastrophic costs, and this was significantly lower in the intervention group (11 participants [21.2%]; 95% CI, 11.1%-34.7%) vs control (continued) Key Points Question Does a digital medication event reminder monitor-observed therapy for patients with tuberculosis result in higher health-related quality of life compared with the standard directly observed therapy? Findings In this secondary analysis of a randomized clinical trial invol...

Financial burden of tuberculosis diagnosis and treatment for patients in Ethiopia: a systematic review and meta-analysis

“…The risk of bias for assessments in cross-sectional studies is summarized in Table 2 . The risk of bias assessment for randomized controlled trials showed that six domains were low risk for bias in one study [ 15 ] and each three domains were also low risk for bias in two studies [ 16 , 17 ]. The rest of the domains was either high risk or unclear for bias.…”

“… The total cost per patient diagnosed was higher for women, rural residents; those who received government food for work support, patients with smear-negative pulmonary tuberculosis, and patients who were not screened for TB in at least one district diagnostic center. Tsegahun, 2022 ( 15 ) Open label RCT. Adults aged 18 years or older with new or previously treated, bacteriologically confirmed, and drug-sensitive pulmonary TB.…”

“…Similarly, on average, 33-76% of annual household income has been lost due to illness and TB treatment [ 21 , 23 ], and around 72% due to MDR-TB illness [ 23 ]. On the contrary, active case finding and households with a health insurance system could reduce TB-related deaths and catastrophic costs [ 10 , 15 , 25 ].…”

Evaluating tuberculosis treatment outcomes in Haiti from 2018 to 2019: A competing risk analysis

“…Adding a social protection component to the TB treatment may improve the treatment outcomes [28] . In addition, implementing a digital medication event reminder may prevent loss to follow-up [ 29 , 30 ].…”

Digital health in the era of COVID-19: Reshaping the next generation of healthcare

“…Inequalities in infrastructure and access to the internet and electricity are among the major challenges in the implementation and scale-up of DHIs in resource-limited settings. Digital health technologies were recommended to help patients adhere to their treatment; however, for optimal implementation of such technologies, trials evaluating the effectiveness of remote treatment are critically needed (19,(27)(28)(29).…”